Logo image of BIAF

BIOAFFINITY TECHNOLOGIES INC (BIAF) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BIAF - US09076W3079 - Common Stock

1.29 USD
-0.09 (-6.52%)
Last: 12/17/2025, 8:00:02 PM
1.27 USD
-0.02 (-1.55%)
After Hours: 12/17/2025, 8:00:02 PM
Fundamental Rating

2

Overall BIAF gets a fundamental rating of 2 out of 10. We evaluated BIAF against 529 industry peers in the Biotechnology industry. Both the profitability and financial health of BIAF have multiple concerns. BIAF does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BIAF has reported negative net income.
In the past year BIAF has reported a negative cash flow from operations.
In the past 5 years BIAF always reported negative net income.
BIAF had a negative operating cash flow in each of the past 5 years.
BIAF Yearly Net Income VS EBIT VS OCF VS FCFBIAF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

BIAF has a worse Return On Assets (-127.65%) than 82.23% of its industry peers.
BIAF has a worse Return On Equity (-165.57%) than 66.92% of its industry peers.
Industry RankSector Rank
ROA -127.65%
ROE -165.57%
ROIC N/A
ROA(3y)-100.74%
ROA(5y)-1117.09%
ROE(3y)-194.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIAF Yearly ROA, ROE, ROICBIAF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

BIAF has a better Gross Margin (27.86%) than 72.59% of its industry peers.
The Profit Margin and Operating Margin are not available for BIAF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 27.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIAF Yearly Profit, Operating, Gross MarginsBIAF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

3

2. Health

2.1 Basic Checks

BIAF does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BIAF has been increased compared to 1 year ago.
BIAF has a worse debt/assets ratio than last year.
BIAF Yearly Shares OutstandingBIAF Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
BIAF Yearly Total Debt VS Total AssetsBIAF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -8.25, we must say that BIAF is in the distress zone and has some risk of bankruptcy.
BIAF has a Altman-Z score of -8.25. This is in the lower half of the industry: BIAF underperforms 69.57% of its industry peers.
BIAF has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
BIAF has a Debt to Equity ratio (0.01) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -8.25
ROIC/WACCN/A
WACC7.91%
BIAF Yearly LT Debt VS Equity VS FCFBIAF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

BIAF has a Current Ratio of 3.65. This indicates that BIAF is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BIAF (3.65) is comparable to the rest of the industry.
A Quick Ratio of 3.64 indicates that BIAF has no problem at all paying its short term obligations.
BIAF's Quick ratio of 3.64 is in line compared to the rest of the industry. BIAF outperforms 45.18% of its industry peers.
Industry RankSector Rank
Current Ratio 3.65
Quick Ratio 3.64
BIAF Yearly Current Assets VS Current LiabilitesBIAF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

BIAF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.38%, which is quite good.
The Revenue for BIAF has decreased by -27.66% in the past year. This is quite bad
EPS 1Y (TTM)13.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.25%
Revenue 1Y (TTM)-27.66%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-38.47%

3.2 Future

BIAF is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.26% yearly.
BIAF is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -12.63% yearly.
EPS Next Y41.46%
EPS Next 2Y29.26%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-36.4%
Revenue Next 2Y-12.63%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

BIAF Yearly Revenue VS EstimatesBIAF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2M 4M 6M 8M
BIAF Yearly EPS VS EstimatesBIAF Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BIAF. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BIAF. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIAF Price Earnings VS Forward Price EarningsBIAF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIAF Per share dataBIAF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as BIAF's earnings are expected to grow with 29.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.26%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BIAF does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BIOAFFINITY TECHNOLOGIES INC

NASDAQ:BIAF (12/17/2025, 8:00:02 PM)

After market: 1.27 -0.02 (-1.55%)

1.29

-0.09 (-6.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)03-30 2026-03-30
Inst Owners8.78%
Inst Owner Change-19.84%
Ins Owners2.77%
Ins Owner Change0%
Market Cap5.80M
Revenue(TTM)6.78M
Net Income(TTM)-14.74M
Analysts43.33
Price TargetN/A
Short Float %1.27%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-69.39%
Min EPS beat(2)-72.11%
Max EPS beat(2)-66.67%
EPS beat(4)1
Avg EPS beat(4)-45.97%
Min EPS beat(4)-72.11%
Max EPS beat(4)1.96%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-8.45%
Min Revenue beat(2)-17.38%
Max Revenue beat(2)0.49%
Revenue beat(4)1
Avg Revenue beat(4)-10.3%
Min Revenue beat(4)-17.38%
Max Revenue beat(4)0.49%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2900%
EPS NY rev (1m)0%
EPS NY rev (3m)-3500%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.86
P/FCF N/A
P/OCF N/A
P/B 0.65
P/tB 0.86
EV/EBITDA N/A
EPS(TTM)-20.94
EYN/A
EPS(NY)-8.26
Fwd EYN/A
FCF(TTM)-1.89
FCFYN/A
OCF(TTM)-1.88
OCFYN/A
SpS1.51
BVpS1.98
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -127.65%
ROE -165.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 27.86%
FCFM N/A
ROA(3y)-100.74%
ROA(5y)-1117.09%
ROE(3y)-194.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.33%
Cap/Sales 0.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.65
Quick Ratio 3.64
Altman-Z -8.25
F-Score4
WACC7.91%
ROIC/WACCN/A
Cap/Depr(3y)740.75%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.25%
EPS Next Y41.46%
EPS Next 2Y29.26%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-27.66%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-38.47%
Revenue Next Year-36.4%
Revenue Next 2Y-12.63%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-47.67%
OCF growth 3YN/A
OCF growth 5YN/A

BIOAFFINITY TECHNOLOGIES INC / BIAF FAQ

Can you provide the ChartMill fundamental rating for BIOAFFINITY TECHNOLOGIES INC?

ChartMill assigns a fundamental rating of 2 / 10 to BIAF.


What is the valuation status of BIOAFFINITY TECHNOLOGIES INC (BIAF) stock?

ChartMill assigns a valuation rating of 1 / 10 to BIOAFFINITY TECHNOLOGIES INC (BIAF). This can be considered as Overvalued.


Can you provide the profitability details for BIOAFFINITY TECHNOLOGIES INC?

BIOAFFINITY TECHNOLOGIES INC (BIAF) has a profitability rating of 1 / 10.


How financially healthy is BIOAFFINITY TECHNOLOGIES INC?

The financial health rating of BIOAFFINITY TECHNOLOGIES INC (BIAF) is 3 / 10.